Company intelligence / Profile preview

Cellartis

Ownership: Private
Employees: ~50
Development stage: Commercial

Overview

Cellartis developed over thirty well-documented human embryonic stem cell lines and proprietary differentiation protocols. The company became a leading supplier of ethically derived hES cells and their derivatives globally. Its technologies enabled advances in drug screening/toxicity testing platforms but did not have direct clinical programs or results.

Therapeutic areas: Other
Modalities: Induced pluripotent stem cell derived therapyStem cell therapyRecombinant protein (for research tools)Biologic (for research tools)
Industry: Non-Drug Biotech

Partnerships

ITI Life Sciences (UK R&D program)University of Glasgow/Dundee University collaborations

Beyond the preview

Go deeper on Cellartis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cellartis.

Explore the full profile